Artivion (NYSE:AORT) Stock Price Down 4.2% - Here's Why

Key Points

• Artivion's stock price experienced a 4.2% decline recently, closing at $40.58, with trading volume down by 91% compared to the average.
• Analysts have mixed reviews, with several upgrades including Stifel Nicolaus raising their target price from $40 to $46, while LADENBURG THALM/SH downgraded their rating and adjusted their price target to $38.80.
• Artivion reported positive financial results, beating analysts' earnings expectations with $0.24 earnings per share and a revenue increase of 15.3% year-over-year.

Shares of Artivion, Inc. (NYSE:AORT - Get Free Report) traded down 4.2% on Wednesday . The company traded as low as $40.76 and last traded at $40.58. 38,224 shares traded hands during trading, a decline of 91% from the average session volume of 444,232 shares. The stock had previously closed at $42.34.

Wall Street Analysts Forecast Growth

AORT has been the topic of several analyst reports. Stifel Nicolaus boosted their target price on Artivion from $40.00 to $46.00 and gave the stock a "buy" rating in a report on Monday. Oppenheimer restated an "outperform" rating on shares of Artivion in a research note on Friday, August 8th. LADENBURG THALM/SH SH downgraded shares of Artivion from a "buy" rating to a "neutral" rating and upped their target price for the stock from $32.00 to $38.80 in a research note on Wednesday, August 13th. Canaccord Genuity Group raised their price target on shares of Artivion from $41.00 to $50.00 and gave the company a "buy" rating in a research report on Monday. Finally, JMP Securities upped their price objective on Artivion from $33.00 to $42.00 and gave the company a "market outperform" rating in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $43.13.

Artivion Stock Down 4.1%

The company has a 50-day moving average of $39.78 and a two-hundred day moving average of $31.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. The company has a market capitalization of $1.92 billion, a PE ratio of -96.60 and a beta of 1.70.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.13. The firm had revenue of $112.97 million for the quarter, compared to analysts' expectations of $107.96 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm's revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Insider Activity at Artivion

In related news, insider John E. Davis sold 10,802 shares of the company's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total transaction of $471,723.34. Following the completion of the transaction, the insider owned 208,778 shares in the company, valued at approximately $9,117,335.26. This represents a 4.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jean F. Holloway sold 10,000 shares of the firm's stock in a transaction on Monday, August 25th. The shares were sold at an average price of $44.37, for a total transaction of $443,700.00. Following the transaction, the senior vice president directly owned 172,129 shares of the company's stock, valued at $7,637,363.73. The trade was a 5.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 74,858 shares of company stock worth $3,250,129. 8.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Illinois Municipal Retirement Fund raised its stake in Artivion by 3.1% during the first quarter. Illinois Municipal Retirement Fund now owns 20,519 shares of the company's stock valued at $504,000 after purchasing an additional 611 shares in the last quarter. Principal Financial Group Inc. increased its stake in Artivion by 2.4% during the first quarter. Principal Financial Group Inc. now owns 206,777 shares of the company's stock worth $5,083,000 after acquiring an additional 4,749 shares during the last quarter. Invesco Ltd. increased its stake in Artivion by 27.9% during the first quarter. Invesco Ltd. now owns 341,656 shares of the company's stock worth $8,398,000 after acquiring an additional 74,589 shares during the last quarter. Fred Alger Management LLC bought a new stake in shares of Artivion in the 1st quarter valued at approximately $2,969,000. Finally, Diker Management LLC bought a new stake in shares of Artivion in the 1st quarter valued at approximately $369,000. 86.37% of the stock is currently owned by institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.